New York, New York -- InvestorsHub NewsWire - March 9,
2021 - PCG Digital -- Hypertension, or high blood pressure as
it's commonly known, affects over three million Americans every
year and is a primary or contributing cause of death for 25% of
them. On a global scale, hypertension kills
roughly 7.6 million
people per year.
Lexaria Bioscience, a Canadian biotech firm specializing in
cannabinoid research, is hoping to change those numbers.
DehydraTECH CBD, the company's revolutionary oral deliverable for
hypertension sufferers, is in human clinical trials right now and
results are promising.
"Our 2018 human clinical trial showed that DehydraTECH CBD
lowers blood pressure by about 5% after just a single 90 milligram
dose," said Lexaria CEO Chris Bunka. "Generic CBD doesn't do that.
Our objective in our new 2021 clinical studies is to evidence a 10%
or greater drop in blood pressure to be competitive with industry
demands."
The 2018 European study also showed evidence of DehydraTECH CBD
facilitating higher volumes of blood flow to the brain and faster
delivery of CBD into the bloodstream. Ensuing studies will
determine what that means for hypertension sufferers.
New Human Clinical Studies are Underway in
2021
Lexaria currently has three human clinical studies about to
commence, using 300 to 450 milligram doses. In comparison, GW
Pharmaceuticals is administering up to 1200 milligrams of
Epidiolex, an FDA-approved CBD-based anti-seizure medicine for
children, and even at those higher doses side
effects have been
minimal.
"In the hypertension industry, drugs that provide a 10 to 20
percent reduction in blood pressure are generally successful,"
Bunka adds. "We are confident we can get to that level and expect
our studies to provide evidence supporting that over the next six
to nine months."
DehydraTECH CBD utilizes a patented dehydration process that
changes how the body senses and absorbs drugs orally. In earlier
clinical trials, DehydraTECH CBD has been proven to deliver over
300% more CBD than generic CBD in less than 30 minutes.
Positive results in the human clinical studies would provide
more evidence for consideration of DehydraTECH CBD as a regulated
form of CBD, a status in the cannabinoid sector that only Epidiolex
has earned to date. Bunka and his team are confident they will get
there.
Hypertension Relief is a $30 Billion Market
There are obvious health care benefits to developing an
effective cannabis-based hypertension treatment. Financially, a
success in this area would be huge for Lexaria. In 2019, the market
for antihypertensive drugs was worth $26.1
billion.
By comparison, the pediatric anti-seizure market that Epidiolex
serves is worth ~$1
billion per year. GW Pharmaceuticals was just purchased
for $7.2 billion by Jazz Pharmaceuticals, a major Big Pharma
player. In the United States alone, there are three
antihypertension drugs that have recorded between $1 and $3 billion
in annual sales:
None of these drugs are cannabis-based and each has unwanted
side effects. Assuming Lexaria reaches that level, the company
could be looking at a drug with over $1 billion in annual revenue
after FDA approval. What might Lexaria be worth at that point?
With existing patents granted in the EU and Australia already
secured for the treatment of heart disease using cannabinoids,
Lexaria is confident it will receive regulator approvals in
multiple geographic markets in due time. Investors seem to agree.
As of this morning, Lexaria (LEXX) was up over 25% since first
listing on Nasdaq in January.
Lexaria is Open to Partnership
Opportunities
CEO Bunka sees the opportunity and is open to partnering with a
larger company. "Lexaria would be open to partner with Big Pharma
to deliver this potentially life-saving treatment," he said. "Our
business model includes out-licensing our technology for
appropriate royalty streams."
Companies with a royalty revenue stream have been known to earn
a valuation of up to 30 times annual revenue. If you do the math on
the partnership possibilities, Lexaria could be looking at
valuations as high as GW Pharmaceuticals recently reached. That's
not unrealistic in this sector.
With Lexaria, it's possible to happen soon as they are not
reliant on government funding to conduct clinical studies: All
existing trials are 100% funded from internal company resources.
Therefore, the ramp-up to commercialization can be faster, and
these potential revenues, can have a significant impact on its
current market cap of only $35 million.
"The Jazz acquisition of GW shows that Big Pharma is finally
taking cannabinoid research and CBD-based medical treatments
seriously," Chris Bunka said. "One of the big benefits of CBD is
its modest side effect profile - pharma simply HAS to research this
thoroughly in the interests of public health."
This story will be worth keeping an eye on as it unfolds.
Results from Q1 studies of DehydraTECH CBD will be made available
starting around May, with human clinical study results to follow
soon thereafter. If all goes well, the path to FDA approval could
become clearer. Relief for hypertension sufferers can't come soon
enough.
Disclaimer:
This communication was produced by PCG Digital Holdings, LLC, an
affiliate of PCG Advisory Inc., (together "PCG"). PCG is an
integrated investor relations, communications and strategic
advisory firm. The information contained on this may be 'Paid
Advertising' for purposes of Section 17(b) of the Securities Act of
1933, as amended (together with the rules and regulations there
under, the "Securities Act"). PCG may be compensated by respective
clients for publicizing information relating to its client's
securities. For more information in terms of compensation received
for services provided by PCG, see the pertinent advertising
materials relating to the respective client. By accessing this Site
and any pages thereof, you agree to be bound by the Terms of Use
and Privacy Policy.
PCG is not a registered or licensed broker, dealer,
broker-dealer, investment adviser nor investment manager, nor does
PCG engage in any activities that would require such registrations.
PCG does not provide investment advice, endorsement, analysis or
recommendations with respect to any securities, and its services to
or statements about its clients should never be construed as any
endorsement of or opinion about any security of any client. No
information contained in this communication constitutes an offer to
sell, a solicitation of an offer to buy, or a recommendation of any
security or any other similar product or service regardless of
whether such security, product, or service is referenced in this
communication. Further, nothing in this communication is intended
to provide tax, legal, or investment advice and nothing in this
communication should be construed as a recommendation to buy, sell
or hold any investment or security or to engage in any investment
strategy or transaction. For full disclaimers, including
compensation received for professional services, please
visit www.pcgadvisory.com/disclosures.
Contact:
info@pcgadvisory.com
Lexaria Bioscience (CSE:LXX)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Lexaria Bioscience (CSE:LXX)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
